Adamis Pharmaceuticals to fund ZIMH study with LUMC opioid expert

Adamis Pharmaceuticals announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center, LUMC, Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression and professor of anesthesiology at the University. Eboo Versi, MD, PhD, CEO of Adamis, said, “These data from the FDA are supported by what we are hearing from first responders having to deal with fentanyl overdoses and poisoning, and this has resulted in tragic consequences….We believe that if ZIMHI demonstrates superiority in reversing fentanyl-induced respiratory depression in patients in the LUMC clinical study, national health organizations will update their emergency protocols to include the use of ZIMHI,” stated Dr. Versi. “Given the increased incidence of fentanyl poisoning, especially when combined with xylazine, there is now a need for a treatment that quickly results in high blood levels of naloxone as effected by ZIMHI. I believe that all first responders and harm reduction groups should have ZIMHI in their toolbox.”